Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in anLower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rates of hospitalizationFor heart failure.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes, and DPP-4 inhibition with saxgliptin did not increase or decrease the rate of ischemic events, though the rates of hospitalization for heart failure was increased.
Type 2 diabetes mellitus
The greatest need is for agents that enhance insulin sensitivity, halt the progressive pancreatic β-cell failure that is characteristic of T2DM and prevent or reverse the microvascular complications.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the…
Guidelines and Expert Consensus documents aim to present management and recommendations based on all of the relevant evidence on a particular subject in order to help physicians to select the best…
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
Sitagliptin significantly improved glycaemia control and was well tolerated in patients with type 2 diabetes mellitus who had inadequate glycaemic control on exercise and diet.
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, it is found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in Patients with HFr EF.
Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ.
It is concluded that in Pima Indians fed a standard diet 1) family membership is the principal determinant of the ratio of fat to carbohydrate oxidation, and 2) a low ratio of fats to carbohydrates is associated with subsequent weight gain independent of low energy expenditure and may contribute to the familial aggregation of obesity.
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
In the context of balanced primary and secondary end points, saxagliptin treatment was associated with an increased risk or hospitalization for heart failure, and this increase in risk was highest among patients with elevated levels of natriuretic peptides, previousheart failure, or chronic kidney disease.